BAUSCH HEALTH COS INC (BHC) Stock Price & Overview

NYSE:BHC • CA0717341071

Current stock price

5.12 USD
+0.04 (+0.79%)
At close:
5.08 USD
-0.04 (-0.78%)
Pre-Market:

The current stock price of BHC is 5.12 USD. Today BHC is up by 0.79%. In the past month the price decreased by -15.23%. In the past year, price decreased by -20.99%.

BHC Key Statistics

52-Week Range4.25 - 8.685
Current BHC stock price positioned within its 52-week range.
1-Month Range4.93 - 6.04
Current BHC stock price positioned within its 1-month range.
Market Cap
1.897B
P/E
1.36
Fwd P/E
1.17
EPS (TTM)
3.77
Dividend Yield
N/A

BHC Stock Performance

Today
+0.79%
1 Week
+1.79%
1 Month
-15.23%
3 Months
-28.89%
Longer-term
6 Months -20.99%
1 Year -20.99%
2 Years -51.74%
3 Years -36.79%
5 Years -83.87%
10 Years N/A

BHC Stock Chart

BAUSCH HEALTH COS INC / BHC Daily stock chart

BHC Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BHC. When comparing the yearly performance of all stocks, BHC is a bad performer in the overall market: 86.09% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BHC Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BHC. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BHC Earnings

On February 20, 2026 BHC reported an EPS of 1.1 and a revenue of 2.80B. The company missed EPS expectations (-13.87% surprise) and beat revenue expectations (2.23% surprise).

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 20, 2026
PeriodQ4 / 2025
EPS Reported$1.10
Revenue Reported2.796B
EPS Surprise -13.87%
Revenue Surprise 2.23%

BHC Forecast & Estimates

9 analysts have analysed BHC and the average price target is 7.43 USD. This implies a price increase of 45.11% is expected in the next year compared to the current price of 5.12.

For the next year, analysts expect an EPS growth of 15.65% and a revenue growth 4.35% for BHC


Analysts
Analysts48.89
Price Target7.43 (45.12%)
EPS Next Y15.65%
Revenue Next Year4.35%

BHC Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

BHC Financial Highlights

Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.77.


Income Statements
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Industry RankSector Rank
PM (TTM) 1.53%
ROA 0.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-4.35%
Sales Q2Q%9.26%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)6.66%

BHC Ownership

Ownership
Inst Owners44.72%
Shares370.56M
Float289.14M
Ins Owners11.42%
Short Float %1.72%
Short Ratio2.36

About BHC

Company Profile

BHC logo image Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

Company Info

IPO: 1994-09-20

BAUSCH HEALTH COS INC

2150 St. Elzear Blvd. West

Laval QUEBEC H7L 4A8 CA

CEO: Joseph C. Papa

Employees: 20300

BHC Company Website

BHC Investor Relations

Phone: 18003611448

BAUSCH HEALTH COS INC / BHC FAQ

What does BAUSCH HEALTH COS INC do?

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.


Can you provide the latest stock price for BAUSCH HEALTH COS INC?

The current stock price of BHC is 5.12 USD. The price increased by 0.79% in the last trading session.


What is the dividend status of BAUSCH HEALTH COS INC?

BHC does not pay a dividend.


How is the ChartMill rating for BAUSCH HEALTH COS INC?

BHC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


On which exchange is BHC stock listed?

BHC stock is listed on the New York Stock Exchange exchange.


What sector and industry does BAUSCH HEALTH COS INC belong to?

BAUSCH HEALTH COS INC (BHC) operates in the Health Care sector and the Pharmaceuticals industry.